The US Preventive Services Task Force is recommending screening all adults for illicit drug use; Senator Chuck Grassley, R-Iowa, is asking the FDA to perform more unannounced inspections of foreign drug manufacturing facilities; 5 years after Congress passed a law to reduce unneccessary diagnostic imaging tests, the law has yet to be implemented.
The US Preventive Services Task Force (USPSTF) has issued a draft recommendation statement recommending that all adults aged 18 years and older be screened for illicit drug use. The task force cited a 2017 national survey in which an estimated 11.5% of adults reported current use of illicit drugs. Illicit drug use is more often reported among young adults aged 18 to 25 years (24.2%) than in older adults (9.5%) or in adolescents aged 12 to 17 years (7.9%). Citing insufficient evidence, USPSTF said it could not assess the benefits and harms of screening for illicit drug use in adolescents.Following HHS’ outlining of a plan to create 2 potential pathways to allow states and other entities to import some prescription drugs intended for foreign markets, Senator Chuck Grassley, R-Iowa, is asking the FDA to perform more unannounced inspections of foreign drug manufacturing facilities. Writing to HHS Secretary Alex Azar and Acting FDA Commissioner Ned Sharpless, MD, Grassley explained that he had learned that the FDA does not track in its databases whether a foreign inspection was subject to an announced or unannounced visit, reported The Center for Biosimilars®.
In 2014, Congress passed a law to reduce unnecessary magnetic resonance imaging, computed tomography scans, and other expensive diagnostic imaging tests that could both harm patients and waste money. However, 5 years later, the law has yet to be implemented and the Trump administration has delayed the law until January 2020, 2 years later than originally planned, according to Kaiser Health News. Even with the 2020 start date, CMS has scheduled next year as a “testing” period, meaning that the agency will still pay for an exam even if the physician doesn’t check the guidelines.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More